JP2001522858A5 - - Google Patents

Download PDF

Info

Publication number
JP2001522858A5
JP2001522858A5 JP2000520458A JP2000520458A JP2001522858A5 JP 2001522858 A5 JP2001522858 A5 JP 2001522858A5 JP 2000520458 A JP2000520458 A JP 2000520458A JP 2000520458 A JP2000520458 A JP 2000520458A JP 2001522858 A5 JP2001522858 A5 JP 2001522858A5
Authority
JP
Japan
Prior art keywords
minutes
merck
eluent
mixture
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000520458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001522858A (ja
Filing date
Publication date
Priority claimed from GBGB9723566.7A external-priority patent/GB9723566D0/en
Application filed filed Critical
Publication of JP2001522858A publication Critical patent/JP2001522858A/ja
Publication of JP2001522858A5 publication Critical patent/JP2001522858A5/ja
Pending legal-status Critical Current

Links

JP2000520458A 1997-11-08 1998-11-06 化合物 Pending JP2001522858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9723566.7A GB9723566D0 (en) 1997-11-08 1997-11-08 Chemical compounds
GB9723566.7 1997-11-08
PCT/EP1998/007022 WO1999024450A2 (en) 1997-11-08 1998-11-06 Adensine a1 receptor agonists

Publications (2)

Publication Number Publication Date
JP2001522858A JP2001522858A (ja) 2001-11-20
JP2001522858A5 true JP2001522858A5 (https=) 2006-01-05

Family

ID=10821742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000520458A Pending JP2001522858A (ja) 1997-11-08 1998-11-06 化合物

Country Status (24)

Country Link
US (1) US6407076B1 (https=)
EP (1) EP1027363B1 (https=)
JP (1) JP2001522858A (https=)
KR (1) KR20010031883A (https=)
CN (1) CN1285842A (https=)
AP (1) AP2000001803A0 (https=)
AT (1) ATE242259T1 (https=)
AU (1) AU1232799A (https=)
BR (1) BR9813973A (https=)
CA (1) CA2309199A1 (https=)
DE (1) DE69815378T2 (https=)
EA (1) EA200000393A1 (https=)
EE (1) EE200000284A (https=)
ES (1) ES2201552T3 (https=)
GB (1) GB9723566D0 (https=)
HR (1) HRP20000276A2 (https=)
HU (1) HUP0004106A2 (https=)
IL (1) IL135965A0 (https=)
IS (1) IS5478A (https=)
NO (1) NO20002360L (https=)
PL (1) PL341091A1 (https=)
SK (1) SK6712000A3 (https=)
TR (1) TR200002157T2 (https=)
WO (1) WO1999024450A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
CA2414623A1 (en) * 2000-08-01 2002-02-07 University Of Virginia Patent Foundation Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1496911B1 (en) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EP2531465A4 (en) * 2010-02-03 2015-12-30 Meh Associates Inc MULTIPLE SUBSTITUTED FLUOROMETHANES AS SELECTIVE AND BIOACTIVE ISOSTERES
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Similar Documents

Publication Publication Date Title
JP2001522858A5 (https=)
JP2001522857A5 (https=)
Adam et al. Routine synthesis of L-[18F] 6-fluorodopa with fluorine-18 acetyl hypofluorite
US5202029A (en) Process for purification of hmg-coa reductase inhibitors
JP2749272B2 (ja) アントラサイクリノングリコシドの精製法
RU2001118849A (ru) Очистка циклопептидных соединений эхинокандина
HU197926B (en) Process for recovering glycopeptide antibiotics
KR960022971A (ko) 들깨유로부터 α-리놀렌산(ALA)을 분리, 정제하는 방법
JP2003534349A (ja) （ｓｓ，ｒｓ）−ｓ−アデノシル−ｌ−メチオニンの薬剤として許容される塩の調製方法
Lin et al. Evaluation of new chiral stationary phases of bonded cyanuric chloride with amino acid and naphthylalkylamine substituents for liquid chromatographic separation of amino acids and amino alcohols as dinitrobenzoyl derivatives
McMahon et al. High-performance liquid chromatographic determination of taurine in human plasma using pre-column extraction and derivatization
Swiderski et al. Polystyrene reverse-phase ion-pair chromatography of chimeric ribozymes
Volland et al. Stereoselective analysis of fenoprofen and its metabolites
CN113061152A (zh) 一种利用氨基型树脂分离纯化甘油葡萄糖苷的方法
JP3141029B2 (ja) ペントスタチンの精製方法
WO2001030796A1 (en) A process for preparing acarbose with high purity
JPH0399259A (ja) クロマトグラフ充填剤及びこれによる水溶性有機化合物の分離法
US4710566A (en) Purification of the messenger RNA cap-binding protein
Yu et al. Enantiomeric separation of fluoxetine derivatives on polysaccharide‐based chiral columns
Contractor et al. The use of Sephadex G-10 in the removal of inorganic salts and urea from rat and human urine prior to chromatography of 5-hydroxyindole metabolites
JP2002504855A (ja) グラディエント溶離法
WO2001014405A3 (en) Methods of obtaining 2-methoxyestradiol of high purity
MIYASHITA et al. Studies on Iodinated Compounds. I. Improved Procedure for Preparation of Monoiodohistidine
JP4070904B2 (ja) イオン化する化合物用の分離剤およびその製造方法
ARAKAWA et al. Improved Synthesis of Sulfoconjugate Isomers of Norepinephrine and Epinephrine, and Separation of All Sulfoconjugates of Catecholamines by Thin-Layer and High-Performance Liquid Chromatography